Hims & Hers Health, Inc. $HIMS Shares Bought by RFG Advisory LLC

RFG Advisory LLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 371.7% during the 4th quarter, Holdings Channel reports. The firm owned 79,081 shares of the company’s stock after purchasing an additional 62,316 shares during the period. RFG Advisory LLC’s holdings in Hims & Hers Health were worth $2,568,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Quent Capital LLC acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Bogart Wealth LLC grew its holdings in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the 1st quarter worth $30,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HIMS. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Leerink Partners lifted their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Bank of America lifted their target price on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Finally, Morgan Stanley decreased their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $31.86.

Insiders Place Their Bets

In other news, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares of the company’s stock, valued at $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 204,857 shares of company stock worth $5,285,706. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $25.68 on Friday. The stock has a market cap of $5.85 billion, a PE ratio of 50.35, a price-to-earnings-growth ratio of 3.67 and a beta of 2.43. The business has a fifty day simple moving average of $22.56 and a 200-day simple moving average of $29.75. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.53 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.